2012 10 20655 https://www.socictopen.socict.org/files/original/533adf9566ced4e597a8e65055b84691.pdf e0d4d428535276c2f92b78a5607bb04f Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Vaccination against COVID-19: Expectations and concerns of patients with autoimmune and rheumatic diseases. Creator An entity primarily responsible for making the resource Renaud Felten, Maxime Dubois, Manuel F Ugarte-Gil, Aurore Chaudier, Lou Kawka, Hugo Bergier, Charlotte Costecalde, Luc Pijnenburg, Jérémy Fort, Emmanuel Chatelus, Christelle Sordet, Rose-Marie Javier, Jacques-Eric Gottenberg, Jean Sibilia, Yurilis Fuentes-Silva, Laurent Arnaud Date A point or period of time associated with an event in the lifecycle of the resource 2021 Identifier An unambiguous reference to the resource within a given context 10.1016/S2665-9913(21)00039-4 Source A related resource from which the described resource is derived The Lancet. Rheumatology https://www.socictopen.socict.org/files/original/9a58157398eb1264a298c43e6dbcce4b.pdf af98bc7368030fbf7aab8603f3820fce Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Vaccination against COVID-19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders. Creator An entity primarily responsible for making the resource Steven W Pipe, Alok Srivastava, Glenn F Pierce, Mike Makris, Flora Peyvandi, Radoslaw Kaczmarek, Magdy El Ekiaby, Daniel P Hart, Cedric Hermans, Declan Noone, Brian O'Mahony, David Page, Thomas Sannié, Uwe Schlenkrich, Mark W Skinner, Amanda Bok Date A point or period of time associated with an event in the lifecycle of the resource 2021 Identifier An unambiguous reference to the resource within a given context 10.1111/hae.14271 Source A related resource from which the described resource is derived Haemophilia : the official journal of the World Federation of Hemophilia https://www.socictopen.socict.org/files/original/ec623877f432e144c428470435a762c2.pdf 10fc18e82bcd76adbae3f99dd7e6f835 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Vaccination boosts protective responses and counters SARS-CoV-2-induced pathogenic memory B cells. Creator An entity primarily responsible for making the resource Pankaj Kumar Mishra, Natalie Bruiners, Rahul Ukey, Pratik Datta, Alberta Onyuka, Deborah Handler, Sabiha Hussain, William Honnen, Sukhwinder Singh, Valentina Guerrini, Yue Yin, Hannah Dewald, Alok Choudhary, Daniel B Horton, Emily S Barrett, Jason Roy, Stanley H Weiss, Patricia Fitzgerald-Bocarsly, Martin J Blaser, Jeffrey L Carson, Reynold A Panettieri, Alfred Lardizabal, Theresa Li-Yun Chang, Abraham Pinter, Maria Laura Gennaro Description An account of the resource Given the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the recent implementation of SARS-CoV-2 vaccination, we have much to learn about the duration of immune protection and the interface between the immune responses to infection and to vaccination. To address these questions, we monitored immune responses to SARS-CoV-2 infection in convalescent individuals over seven months and following mRNA vaccination. Spike Receptor-Binding-Domain (RBD)-specific circulating antibodies and plasma neutralizing activity generally decreased over time, whereas RBD-specific memory B cells persisted. Additionally, using antibody depletion techniques, we showed that the neutralizing activity of plasma specifically resides in the anti-RBD antibodies. More vigorous antibody and B cell responses to vaccination were observed in previously infected subjects relative to uninfected comparators, presumably due to immune priming by infection. SARS-CoV-2 infection also led to increased numbers of double negative B memory cells, which are described as a dysfunctional B cell subset. This effect was reversed by SARS-CoV-2 vaccination, providing a potential mechanistic explanation for the vaccination-induced reduction in symptoms in patients with Long-COVID"." Date A point or period of time associated with an event in the lifecycle of the resource 2021 Identifier An unambiguous reference to the resource within a given context 10.1101/2021.04.11.21255153 Source A related resource from which the described resource is derived medRxiv : the preprint server for health sciences https://www.socictopen.socict.org/files/original/a5dcd6d867bf22b9884d5843b18a6960.pdf 2853c8004c392e1e2440691f512bf4d8 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Vaccination Prioritization Strategies for COVID-19 in Korea: A Mathematical Modeling Approach Creator An entity primarily responsible for making the resource Chang Hyeong Lee, Yongin Choi, James Slghee Kim, Heejin Choi, Jung-Eun Kim Description An account of the resource Coronavirus disease 2019 (COVID-19) vaccination has recently started worldwide. As the vaccine supply will be limited for a considerable period of time in many countries, it is important to devise the effective vaccination strategies that reduce the number of deaths and incidence of infection. One of the characteristics of COVID-19 is that the symptom, severity, and mortality of the disease differ by age. Thus, when the vaccination supply is limited, age-dependent vaccination priority strategy should be implemented to minimize the incidences and mortalities. In this study, we developed an age-structured model for describing the transmission dynamics of COVID-19, including vaccination. Using the model and actual epidemiological data in Korea, we estimated the infection probability for each age group under different levels of social distancing implemented in Korea and investigated the effective age-dependent vaccination strategies to reduce the confirmed cases and fatalities of COVID-19. We found that, in a lower level of social distancing, vaccination priority for the age groups with the highest transmission rates will reduce the incidence mostly, but, in higher levels of social distancing, prioritizing vaccination for the elderly age group reduces the infection incidences more effectively. To reduce mortalities, vaccination priority for the elderly age group is the best strategy in all scenarios of levels of social distancing. Furthermore, we investigated the effect of vaccine supply and efficacy on the reduction in incidence and mortality. Date A point or period of time associated with an event in the lifecycle of the resource 2021 Subject The topic of the resource Mathematical modeling, covid-19, social distancing, vaccination priority strategy Identifier An unambiguous reference to the resource within a given context 10.3390/ijerph18084240 Source A related resource from which the described resource is derived Epidemiology and Health Publisher An entity responsible for making the resource available Korean Society of Epidemiology Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Medicine https://www.socictopen.socict.org/files/original/d7a8ad6938ffdc2a730672b25cc0c56e.pdf 1b3e7f57b100f69c1b5b7b9ef49fefb8 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Vaccination willingness, vaccine hesitancy, and estimated coverage at the first round of COVID-19 vaccination in China: A national cross-sectional study. Creator An entity primarily responsible for making the resource Chao Wang, Bingfeng Han, Tianshuo Zhao, Hanyu Liu, Bei Liu, Linyi Chen, Mingzhu Xie, Jiang Liu, Hui Zheng, Sihui Zhang, Yu Wang, Ninghua Huang, Juan Du, Ya-Qiong Liu, Qing-Bin Lu, Fuqiang Cui Description An account of the resource Vaccination against coronavirus disease 2019 (COVID-19) has become an important public health solution. To date, there has been a lack of data on COVID-19 vaccination willingness, vaccine hesitancy, and vaccination coverage in China since the vaccine has become available. We designed and implemented a cross-sectional, population-based online survey to evaluate the willingness, hesitancy, and coverage of the COVID-19 vaccine among the Chinese population. 8742 valid samples were recruited and classified as the vaccine-priority group (n = 3902; 44.6%) and the non-priority group (n = 4840; 55.4%). The proportion of people's trust in the vaccine, delivery system, and government were 69.0%, 78.0% and 81.3%, respectively. 67.1% of the participants were reportedly willing to accept the COVID-19 vaccination, while 9.0% refused it. 834 (35.5%) reported vaccine hesitancy, including acceptors with doubts (48.8%), refusers (39.4%), and delayers (11.8%). The current coverage was 34.4%, far from reaching the requirements of herd immunity. The predicted rate of COVID-19 vaccination was 64.9%, 68.9% and 81.1% based on the rates of vaccine hesitancy, willingness, and refusal, respectively. The COVID-19 vaccine rate is far from reaching the requirements of herd immunity, which will require more flexible and comprehensive efforts to improve the population's confidence and willingness to vaccinate. It should be highlighted that vaccination alone is insufficient to stop the pandemic; further efforts are needed not only to increase vaccination coverage but also to maintain non-specific prevention strategies. Date A point or period of time associated with an event in the lifecycle of the resource 2021 Subject The topic of the resource Vaccination, covid-19 vaccine, Vaccine hesitancy, willingness, Confidence Identifier An unambiguous reference to the resource within a given context 10.1016/j.vaccine.2021.04.020 Source A related resource from which the described resource is derived Vaccine https://www.socictopen.socict.org/files/original/1a43783715e79ef00703aede4cd8558d.pdf 6cf255177108e95ab1623a53c4b648f8 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Vaccine Candidates Against Coronavirus Infections. Where Does COVID-19 Stand? Creator An entity primarily responsible for making the resource Jawad Al-Kassmy, Jannie Pedersen, Gary Kobinger Description An account of the resource Seven years after the Middle East respiratory syndrome (MERS) outbreak, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) made its first appearance in a food market in Wuhan, China, drawing an entirely new course to our lives. As the virus belongs to the same genus of MERS and SARS, researchers have been trying to draw lessons from previous outbreaks to find a potential cure. Although there were five Phase I human vaccine trials against SARS and MERS, the lack of data in humans provided us with limited benchmarks that could help us design a new vaccine for Coronavirus disease 2019 (COVID-19). In this review, we showcase the similarities in structures of virus components between SARS-CoV, MERS-CoV, and SARS-CoV-2 in areas relevant to vaccine design. Using the ClinicalTrials.gov and World Health Organization (WHO) databases, we shed light on the 16 current approved clinical trials worldwide in search for a COVID-19 vaccine. The different vaccine platforms being tested are Bacillus Calmette–Guérin (BCG) vaccines, DNA and RNA-based vaccines, inactivated vaccines, protein subunits, and viral vectors. By thoroughly analyzing different trials and platforms, we also discuss the advantages and disadvantages of using each type of vaccine and how they can contribute to the design of an adequate vaccine for COVID-19. Studying past efforts invested in conducting vaccine trials for MERS and SARS will provide vital insights regarding the best approach to designing an effective vaccine against COVID-19. Date A point or period of time associated with an event in the lifecycle of the resource 2020 Subject The topic of the resource coronavirus, MERS, SARS, vaccine, covid-19, Clinical trials Identifier An unambiguous reference to the resource within a given context 10.3390/v12080861 Source A related resource from which the described resource is derived Epidemiology and Health Publisher An entity responsible for making the resource available Korean Society of Epidemiology Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Microbiology https://www.socictopen.socict.org/files/original/f60e3c92a8286561221e7126d655d4cf.pdf 91dfb743c2cc4acf33918f40bf835681 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Vaccine Design from the Ensemble of Surface Glycoprotein Epitopes of SARS-CoV-2: An Immunoinformatics Approach Creator An entity primarily responsible for making the resource Noor Rahman, Zarrin Basharat, Haroon Khan, Kamil Kuča, Fawad Ali, Muhammad Shehroz, Muhammad Kazim Khan, Philippe Jeandet, Eugenie Nepovimova Description An account of the resource The present study aimed to work out a peptide-based multi-epitope vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We predicted different B-cell and T-cell epitopes by using the Immune Epitopes Database (IEDB). Homology modeling of the construct was done using SWISS-MODEL and then docked with different toll-like-receptors (TLR4, TLR7, and TLR8) using PatchDock, HADDOCK, and FireDock, respectively. From the overlapped epitopes, we designed five vaccine constructs C1–C5. Based on antigenicity, allergenicity, solubility, different physiochemical properties, and molecular docking scores, we selected the vaccine construct 1 (C1) for further processing. Docking of C1 with TLR4, TLR7, and TLR8 showed striking interactions with global binding energy of −43.48, −65.88, and −60.24 Kcal/mol, respectively. The docked complex was further simulated, which revealed that both molecules remain stable with minimum RMSF. Activation of TLRs induces downstream pathways to produce pro-inflammatory cytokines against viruses and immune system simulation shows enhanced antibody production after the booster dose. In conclusion, C1 was the best vaccine candidate among all designed constructs to elicit an immune response SARS-CoV-2 and combat the coronavirus disease (COVID-19). Date A point or period of time associated with an event in the lifecycle of the resource 2020 Subject The topic of the resource coronavirus, vaccine, antigenicity, pneumonia, allergenicity, multi-epitopes Identifier An unambiguous reference to the resource within a given context 10.3390/vaccines8030423 Source A related resource from which the described resource is derived Epidemiology and Health Publisher An entity responsible for making the resource available Korean Society of Epidemiology Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Medicine https://www.socictopen.socict.org/files/original/4bd278afdfc4e876980c8109c0c77a1f.pdf 03f1379411daff7363adaeb292029964 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Vaccine development in the SARS-CoV-2 pandemic: a balancing act on accuracy and speed. Creator An entity primarily responsible for making the resource Sergio Linares-Fernández, Peter Francis Raguindin Date A point or period of time associated with an event in the lifecycle of the resource 2020 Identifier An unambiguous reference to the resource within a given context 10.1007/s00038-020-01511-2 Source A related resource from which the described resource is derived International journal of public health https://www.socictopen.socict.org/files/original/e425bf1e221b881887593f735c7743b1.pdf 7c62593775f33141cacc3e0aff4859fb Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. Creator An entity primarily responsible for making the resource Damon Deming, Timothy Sheahan, Mark Heise, Boyd Yount, Nancy Davis, Amy Sims, Mehul Suthar, Jack Harkema, Alan Whitmore, Raymond Pickles, Ande West, Eric Donaldson, Kristopher Curtis, Robert Johnston, Ralph Baric Description An account of the resource In 2003, severe acute respiratory syndrome coronavirus (SARS-CoV) was identified as the etiological agent of severe acute respiratory syndrome, a disease characterized by severe pneumonia that sometimes results in death. SARS-CoV is a zoonotic virus that crossed the species barrier, most likely originating from bats or from other species including civets, raccoon dogs, domestic cats, swine, and rodents. A SARS-CoV vaccine should confer long-term protection, especially in vulnerable senescent populations, against both the 2003 epidemic strains and zoonotic strains that may yet emerge from animal reservoirs. We report the comprehensive investigation of SARS vaccine efficacy in young and senescent mice following homologous and heterologous challenge.Using Venezuelan equine encephalitis virus replicon particles (VRP) expressing the 2003 epidemic Urbani SARS-CoV strain spike (S) glycoprotein (VRP-S) or the nucleocapsid (N) protein from the same strain (VRP-N), we demonstrate that VRP-S, but not VRP-N vaccines provide complete short- and long-term protection against homologous strain challenge in young and senescent mice. To test VRP vaccine efficacy against a heterologous SARS-CoV, we used phylogenetic analyses, synthetic biology, and reverse genetics to construct a chimeric virus (icGDO3-S) encoding a synthetic S glycoprotein gene of the most genetically divergent human strain, GDO3, which clusters among the zoonotic SARS-CoV. icGD03-S replicated efficiently in human airway epithelial cells and in the lungs of young and senescent mice, and was highly resistant to neutralization with antisera directed against the Urbani strain. Although VRP-S vaccines provided complete short-term protection against heterologous icGD03-S challenge in young mice, only limited protection was seen in vaccinated senescent animals. VRP-N vaccines not only failed to protect from homologous or heterologous challenge, but resulted in enhanced immunopathology with eosinophilic infiltrates within the lungs of SARS-CoV-challenged mice. VRP-N-induced pathology presented at day 4, peaked around day 7, and persisted through day 14, and was likely mediated by cellular immune responses.This study identifies gaps and challenges in vaccine design for controlling future SARS-CoV zoonosis, especially in vulnerable elderly populations. The availability of a SARS-CoV virus bearing heterologous S glycoproteins provides a robust challenge inoculum for evaluating vaccine efficacy against zoonotic strains, the most likely source of future outbreaks. Date A point or period of time associated with an event in the lifecycle of the resource 2006 Identifier An unambiguous reference to the resource within a given context DOI: 10.1371/journal.pmed.0030525 Source A related resource from which the described resource is derived PLoS Medicine Publisher An entity responsible for making the resource available Public Library of Science (PLoS) Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Medicine Language A language of the resource EN https://www.socictopen.socict.org/files/original/8265608d09a2b0cd42eecbdd69aaa839.pdf d663d7e17d82d4abf1686953ecc912df Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Creator An entity primarily responsible for making the resource Sebastien Ourselin, Mark S Graham, Liane S Canas, Benjamin Murray, Marc Modat, Jonathan Wolf, Kerstin Klaser, Michela Antonelli, Anna May, Lorenzo Polidori, Somesh Selvachandran, Christina Hu, Joan Capdevila, Cristina Menni, Panayiotis Louca, Carole H Sudre, Long H Nguyen, David A Drew, Jordi Merino, Erika Molteni, Amit D Joshi, Massimo Mangino, Alexander Hammers, Anna L Goodman, Andrew T Chan, Claire J Steves, Ana M Valdes, Tim D Spector Description An account of the resource The Pfizer-BioNTech (BNT162b2) and the Oxford-AstraZeneca (ChAdOx1 nCoV-19) COVID-19 vaccines have shown excellent safety and efficacy in phase 3 trials. We aimed to investigate the safety and effectiveness of these vaccines in a UK community setting. In this prospective observational study, we examined the proportion and probability of self-reported systemic and local side-effects within 8 days of vaccination in individuals using the COVID Symptom Study app who received one or two doses of the BNT162b2 vaccine or one dose of the ChAdOx1 nCoV-19 vaccine. We also compared infection rates in a subset of vaccinated individuals subsequently tested for SARS-CoV-2 with PCR or lateral flow tests with infection rates in unvaccinated controls. All analyses were adjusted by age (≤55 years vs >55 years), sex, health-care worker status (binary variable), obesity (BMI <30 kg/m2vs ≥30 kg/m2), and comorbidities (binary variable, with or without comorbidities). Between Dec 8, and March 10, 2021, 627 383 individuals reported being vaccinated with 655 590 doses: 282 103 received one dose of BNT162b2, of whom 28 207 received a second dose, and 345 280 received one dose of ChAdOx1 nCoV-19. Systemic side-effects were reported by 13·5% (38 155 of 282 103) of individuals after the first dose of BNT162b2, by 22·0% (6216 of 28 207) after the second dose of BNT162b2, and by 33·7% (116 473 of 345 280) after the first dose of ChAdOx1 nCoV-19. Local side-effects were reported by 71·9% (150 023 of 208 767) of individuals after the first dose of BNT162b2, by 68·5% (9025 of 13 179) after the second dose of BNT162b2, and by 58·7% (104 282 of 177 655) after the first dose of ChAdOx1 nCoV-19. Systemic side-effects were more common (1·6 times after the first dose of ChAdOx1 nCoV-19 and 2·9 times after the first dose of BNT162b2) among individuals with previous SARS-CoV-2 infection than among those without known past infection. Local effects were similarly higher in individuals previously infected than in those without known past infection (1·4 times after the first dose of ChAdOx1 nCoV-19 and 1·2 times after the first dose of BNT162b2). 3106 of 103 622 vaccinated individuals and 50 340 of 464 356 unvaccinated controls tested positive for SARS-CoV-2 infection. Significant reductions in infection risk were seen starting at 12 days after the first dose, reaching 60% (95% CI 49-68) for ChAdOx1 nCoV-19 and 69% (66-72) for BNT162b2 at 21-44 days and 72% (63-79) for BNT162b2 after 45-59 days. Systemic and local side-effects after BNT162b2 and ChAdOx1 nCoV-19 vaccination occur at frequencies lower than reported in phase 3 trials. Both vaccines decrease the risk of SARS-CoV-2 infection after 12 days. ZOE Global, National Institute for Health Research, Chronic Disease Research Foundation, National Institutes of Health, UK Medical Research Council, Wellcome Trust, UK Research and Innovation, American Gastroenterological Association. Date A point or period of time associated with an event in the lifecycle of the resource 2021 Identifier An unambiguous reference to the resource within a given context 10.1016/S1473-3099(21)00224-3 Source A related resource from which the described resource is derived The Lancet. Infectious diseases